Gene Therapy for Metastatic Castration-Resistant Prostate Cancer Using the JC Polyomavirus (JCPyV) Virus-Like Particles as a Gene Delivery Vector.
The study suggests that JCPyV-derived virus-like particles could inhibit tumor growth in metastatic CRPC, but no significant survival benefits were observed compared to standard treatments.
Where it sits
this study against the rest of the leuprorelin corpusSummary and findings
This study evaluated the therapeutic efficacy of JC polyomavirus (JCPyV) virus-like particles (VLPs) carrying a suicide gene in a mouse model of metastatic castration-resistant prostate cancer (CRPC). The treatment was compared to enzalutamide/leuprorelin acetate (ENZ/LEU) and assessed using fluorescence molecular tomography. No significant differences in survival were observed among the treatment groups.
Abstract
<h4>Background</h4>Systemic metastasis remains the leading cause of mortality in patients with advanced prostate cancer, particularly in castration-resistant prostate cancer (CRPC), for which effective systemic therapeutic options are limited. Gene therapy is a potential strategy for achieving selective tumor targeting and systemic disease control in metastatic settings. This study aimed to establish a systemic metastasis animal model for CRPC and evaluate the therapeutic efficacy of JC polyomavirus (JCPyV) virus-like particle (VLPs)-based gene therapy against metastatic disease.<h4>Methods</h4>A near-infrared fluorescent protein (iRFP)-expressing CRPC cell line was used to establish a systemic metastasis model by tail-vein injection in mice. The therapeutic efficacy of JCPyV VLPs carrying a prostate-specific antigen (PSA) promoter-driven suicide gene (PSAtk-VLPs), administered in combination with ganciclovir (GCV), was evaluated longitudinally by fluorescence molecular tomography (FMT), with enzalutamide/leuprorelin acetate (ENZ/LEU) included as a clinical treatment comparator.<h4>Results</h4>CRPC metastases in the lungs, liver, spleen, kidneys, and bones were detected by FMT in real time. Control mice exhibited exponential CRPC growth, whereas ENZ/LEU treatment delayed CRPC progression. PSAtk-VLPs/GCV significantly inhibited the growth of metastatic CRPC. However, no significant differences in survival were observed among the MOCK, ENZ/LEU, and PSAtk-VLP/GCV groups (log-rank test, p = 0.7351).<h4>Conclusion</h4>These findings support that JCPyV-derived virus-like particles constitute a promising therapeutic approach for metastatic CRPC, enabling systemic delivery of suicide gene therapy with selective inhibition of tumor growth and translational relevance.
Background
This paper addresses the challenge of systemic metastasis in advanced prostate cancer, particularly in castration-resistant prostate cancer (CRPC), where treatment options are limited. Previous studies have explored various therapeutic strategies, but gene therapy remains a promising area for targeted treatment. This study aims to evaluate the efficacy of JCPyV VLPs as a gene delivery vector in a CRPC model.
Methods
A near-infrared fluorescent protein-expressing CRPC cell line was injected into mice via the tail vein to establish a systemic metastasis model. The therapeutic efficacy of JCPyV VLPs carrying a prostate-specific antigen promoter-driven suicide gene, administered with ganciclovir, was assessed using fluorescence molecular tomography. Enzalutamide/leuprorelin acetate served as a clinical treatment comparator.
Results
CRPC metastases were detected in the lungs, liver, spleen, kidneys, and bones using fluorescence molecular tomography. Control mice showed exponential growth of CRPC, while ENZ/LEU treatment delayed progression. PSAtk-VLPs/GCV significantly inhibited metastatic CRPC growth, but no significant survival differences were found among the treatment groups (log-rank test, p=0.7351).
Interpretation
The findings suggest that while JCPyV VLPs may inhibit tumor growth, the lack of significant survival differences indicates that the clinical impact may be limited. This study adds to the body of literature on gene therapy for CRPC but highlights the need for further investigation, especially regarding survival outcomes. Confounding factors include the use of an animal model and the absence of significant clinical endpoints.
Key findings
- Control mice exhibited exponential CRPC growth.
- ENZ/LEU treatment delayed CRPC progression.
- PSAtk-VLPs/GCV significantly inhibited the growth of metastatic CRPC.
- No significant differences in survival were observed among the MOCK, ENZ/LEU, and PSAtk-VLP/GCV groups (log-rank test, p=0.7351).
Limitations
- Based on an animal model, results may not translate to humans.
- No significant survival differences among treatment groups.
- Short follow-up duration limits assessment of long-term effects.
- Single-site study may not represent broader populations.